A comprehensive Cochrane systematic review analyzing data from 14 randomized clinical trials including over 100,000 participants globally confirms that respiratory syncytial virus (RSV) vaccines have robust safety profiles and demonstrate significant efficacy in preventing RSV infection in vulnerable populations. These findings solidify the vaccines’ role in public health strategies targeting a common respiratory pathogen with serious morbidity in infants and older adults.